Nanjing Leads Biolabs Co Ltd

Company Profile

• Business description

  Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. It has one Core Product, LBL-024 (registrational-stage PD-L1 and 4-1BB dual-targeting bispecific antibody), which it is evaluating for its therapeutic potential in extra-pulmonary neuroendocrine carcinoma both as monotherapy for patients who have received at least three prior lines of therapy and part of combination therapy as first-line treatment (1L), as well as in small cell lung cancer as 1L treatment, biliary tract cancer as 1L/1L+ treatment, non-small cell lung cancer as 1L/1L+ treatment, and other solid tumors in patients who have received at least two prior lines of therapy.

• Contact

  18E, Jialingjiang Street
  Floor 8, Building 03
  Jiangsu
  Nanjing210019
  CHN

  T: +86 2558862889

  https://www.leadsbiolabs.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2025

  Employees

  192